PL3439649T3 - Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanie - Google Patents
Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanieInfo
- Publication number
- PL3439649T3 PL3439649T3 PL17723734.4T PL17723734T PL3439649T3 PL 3439649 T3 PL3439649 T3 PL 3439649T3 PL 17723734 T PL17723734 T PL 17723734T PL 3439649 T3 PL3439649 T3 PL 3439649T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical formulations
- delayed release
- release pharmaceutical
- valproic acid
- valproic
- Prior art date
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title 2
- 230000003111 delayed effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229960000604 valproic acid Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606197 | 2016-04-08 | ||
| PCT/GB2017/051002 WO2017175013A1 (en) | 2016-04-08 | 2017-04-10 | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3439649T3 true PL3439649T3 (pl) | 2024-03-18 |
Family
ID=58709491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17723734.4T PL3439649T3 (pl) | 2016-04-08 | 2017-04-10 | Preparaty farmaceutyczne o opóźnionym uwalnianiu zawierające kwas walproinowy i ich zastosowanie |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11395808B2 (enExample) |
| EP (1) | EP3439649B1 (enExample) |
| JP (1) | JP6985368B2 (enExample) |
| KR (1) | KR102438395B1 (enExample) |
| CN (2) | CN109414423A (enExample) |
| AU (1) | AU2017246697B2 (enExample) |
| ES (1) | ES2969021T3 (enExample) |
| HU (1) | HUE064701T2 (enExample) |
| IL (1) | IL262163B2 (enExample) |
| MX (1) | MX395521B (enExample) |
| PL (1) | PL3439649T3 (enExample) |
| RU (1) | RU2760304C2 (enExample) |
| WO (1) | WO2017175013A1 (enExample) |
| ZA (1) | ZA201806766B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| US11395808B2 (en) | 2016-04-08 | 2022-07-26 | Cereno Scientific Ab | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof |
| CN113995742B (zh) * | 2021-10-22 | 2023-12-29 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 包含丙戊酸的美白组合物及其用途 |
| GB2613900B (en) * | 2021-12-20 | 2024-01-17 | Cereno Scient Ab | Novel compounds and methods of use thereof |
| WO2026068561A1 (en) | 2024-09-24 | 2026-04-02 | Cereno Scientific Ab | Valproic acid for use in treating pulmonary arterial hypertension |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3773926D1 (de) | 1987-07-22 | 1991-11-21 | Farvalsa Ag | Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung. |
| HK1042427A1 (zh) * | 1999-09-30 | 2002-08-16 | Penwest Pharmaceuticals Co. | 用於高溶度药物的持续释放基质方法 |
| AT408718B (de) * | 1999-12-02 | 2002-02-25 | Gerot Pharmazeutika | Natriumvalproat-granulat mit verringerter hygroskopizität |
| WO2002055017A2 (en) | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
| US6610326B2 (en) * | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
| ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| JP2006507297A (ja) | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US20040224006A1 (en) | 2003-04-21 | 2004-11-11 | Samn Raffaniello | Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation |
| ITMI20040876A1 (it) | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
| US20050276848A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release neutralized divalproex sodium |
| US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| WO2006117165A2 (en) | 2005-05-02 | 2006-11-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Means and methods for the treatment of head injuries and stroke |
| EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| CA2621560A1 (en) | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
| EP1937650B1 (en) | 2005-09-08 | 2011-06-15 | S*BIO Pte Ltd | Heterocyclic compounds |
| US20070082046A1 (en) * | 2005-10-11 | 2007-04-12 | Banner Pharmacaps, Inc. | Enteric valproic acid |
| ES2317450T3 (es) * | 2006-01-11 | 2009-04-16 | Teva Pharmaceutical Industries Ltd. | Formulacion de liberacion controlada de acido valproico y sus derivados. |
| US20100061984A1 (en) | 2006-01-20 | 2010-03-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| EP2004234A2 (en) | 2006-04-06 | 2008-12-24 | Novartis AG | Combination of organic compounds |
| NZ575171A (en) | 2006-08-31 | 2012-04-27 | Aptalis Pharmatech Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
| GB2454118B (en) | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| WO2009009737A1 (en) * | 2007-07-12 | 2009-01-15 | Neurosci, Inc. | Sustained release formulation of active pharmaceuticals in a lipid based sustained release |
| US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| GB201003766D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| US20110245154A1 (en) | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
| CN101947209B (zh) * | 2010-07-21 | 2012-07-25 | 河南中帅医药科技发展有限公司 | 双丙戊酸钠小丸及其制备方法 |
| PL2683371T3 (pl) * | 2011-03-09 | 2021-04-19 | Cereno Scientific Ab | Związki i sposoby poprawy zaburzonej funkcji wewnątrzustrojowej fibrynolizy przy zastosowaniu inhibitorów deacetylazy histonowej |
| UA110853C2 (uk) | 2011-09-13 | 2016-02-25 | Фармасайклікс, Інк. | Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування |
| CN104248627A (zh) * | 2013-06-25 | 2014-12-31 | 北大方正集团有限公司 | 丙戊酸半钠泡腾干混悬剂及其制备方法 |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| WO2017175010A1 (en) | 2016-04-08 | 2017-10-12 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
| US11395808B2 (en) | 2016-04-08 | 2022-07-26 | Cereno Scientific Ab | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof |
-
2017
- 2017-04-10 US US16/090,664 patent/US11395808B2/en active Active
- 2017-04-10 EP EP17723734.4A patent/EP3439649B1/en active Active
- 2017-04-10 HU HUE17723734A patent/HUE064701T2/hu unknown
- 2017-04-10 WO PCT/GB2017/051002 patent/WO2017175013A1/en not_active Ceased
- 2017-04-10 MX MX2018012224A patent/MX395521B/es unknown
- 2017-04-10 JP JP2019503794A patent/JP6985368B2/ja active Active
- 2017-04-10 AU AU2017246697A patent/AU2017246697B2/en active Active
- 2017-04-10 CN CN201780025746.XA patent/CN109414423A/zh active Pending
- 2017-04-10 RU RU2018137399A patent/RU2760304C2/ru active
- 2017-04-10 KR KR1020187031904A patent/KR102438395B1/ko active Active
- 2017-04-10 ES ES17723734T patent/ES2969021T3/es active Active
- 2017-04-10 PL PL17723734.4T patent/PL3439649T3/pl unknown
- 2017-04-10 CN CN202111575415.8A patent/CN114209667A/zh active Pending
-
2018
- 2018-10-07 IL IL262163A patent/IL262163B2/en unknown
- 2018-10-11 ZA ZA2018/06766A patent/ZA201806766B/en unknown
-
2022
- 2022-07-19 US US17/868,323 patent/US12023311B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3018043A1 (en) | 2017-10-12 |
| AU2017246697B2 (en) | 2022-06-02 |
| JP2019510834A (ja) | 2019-04-18 |
| MX395521B (es) | 2025-03-25 |
| ES2969021T3 (es) | 2024-05-16 |
| US12023311B2 (en) | 2024-07-02 |
| AU2017246697A1 (en) | 2018-10-04 |
| WO2017175013A1 (en) | 2017-10-12 |
| CN114209667A (zh) | 2022-03-22 |
| NZ746269A (en) | 2024-10-25 |
| US20230120670A1 (en) | 2023-04-20 |
| JP6985368B2 (ja) | 2021-12-22 |
| EP3439649C0 (en) | 2023-11-15 |
| EP3439649B1 (en) | 2023-11-15 |
| RU2018137399A3 (enExample) | 2020-06-18 |
| MX2018012224A (es) | 2019-05-16 |
| IL262163B1 (en) | 2023-03-01 |
| EP3439649A1 (en) | 2019-02-13 |
| ZA201806766B (en) | 2024-03-27 |
| HUE064701T2 (hu) | 2024-04-28 |
| US20190111011A1 (en) | 2019-04-18 |
| US11395808B2 (en) | 2022-07-26 |
| RU2760304C2 (ru) | 2021-11-23 |
| IL262163B2 (en) | 2023-07-01 |
| CN109414423A (zh) | 2019-03-01 |
| BR112018070626A2 (pt) | 2019-02-05 |
| IL262163A (en) | 2018-11-29 |
| KR20180127480A (ko) | 2018-11-28 |
| RU2018137399A (ru) | 2020-05-12 |
| KR102438395B1 (ko) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304732A (en) | Orally administered amino acid compositions with a modified release | |
| IL256085B (en) | A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment | |
| IL290114A (en) | Pharmaceutical preparations, their preparation and uses | |
| EP3102585A4 (en) | Boronic acid esters and pharmaceutical formulations thereof | |
| ZA201806766B (en) | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof | |
| IL262929B1 (en) | Preparations for treatment, methods of their preparation and their uses | |
| ZA201905379B (en) | 1-amino-1-cyclopropanecaboxylic acid formulations | |
| LT3223796T (lt) | Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai | |
| IL257143A (en) | Cetylated fatty acids, a system for their preparation and use | |
| IL252397A0 (en) | Pharmaceutical preparations, their preparation and uses | |
| LT3229843T (lt) | Farmacinė kompozicija, jos paruošimo būdas ir naudojimas | |
| SG10202008700VA (en) | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| SG11201704971UA (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
| IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
| PL3253857T3 (pl) | Preparaty wodne, ich wytwarzanie i zastosowanie | |
| GB201511863D0 (en) | Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same |